Windtree Therapeutics Inc [WINT] stock is trading at $0.41, down -3.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The WINT shares have gain 12.02% over the last week, with a monthly amount glided 7.44%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, April 2024, Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing. In a post published today on Yahoo Finance, Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. (“Varian”) to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing.
From an analyst’s perspective:
Windtree Therapeutics Inc [NASDAQ: WINT] stock has seen the most recent analyst activity on June 26, 2020, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $12.25.
Windtree Therapeutics Inc [WINT] stock has fluctuated between $0.28 and $18.48 over the past year. Windtree Therapeutics Inc [NASDAQ: WINT] shares were valued at $0.41 at the most recent close of the market.
Analyzing the WINT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -2.8 and Total Capital is -0.82. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3942 points at the first support level, and at 0.3785 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4284, and for the 2nd resistance point, it is at 0.4469.
Windtree Therapeutics Inc [WINT] reported earnings per share of -$0.86 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.63/share, meaning a difference of -$0.23 and a surprise factor of -36.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.64 per share as compared to estimates of -$0.68 per share, a difference of -$0.96 representing a surprise of -141.20%.
Ratios To Look Out For
For context, Windtree Therapeutics Inc’s Current Ratio is 2.40. Also, the Quick Ratio is 2.40, while the Cash Ratio stands at 1.99.
Transactions by insiders
Recent insider trading involved Fraser Craig, President and CEO, that happened on Sep 27 ’23 when 2500.0 shares were purchased. President and CEO, Fraser Craig completed a deal on Sep 26 ’23 to buy 2500.0 shares. Meanwhile, President and CEO Fraser Craig bought 1497.0 shares on Apr 26 ’23.
